<DOC>
	<DOC>NCT00956280</DOC>
	<brief_summary>The purpose of this study is to characterize the demographic and clinical aspects, and describe the frequency and type of KRAS mutation in a Brazilian population sample with advanced non-small cell lung cancer (NSCLC).</brief_summary>
	<brief_title>Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Histological or cytological confirmation of locally advanced or metastatic Non Small Cell Lung Cancer (IIIBIV) Tumour sample (block of slides) available for KRAS analysis Confirmation of locally advanced or metastatic NSCLC (IIIBIV) exclusively by cytology, with no tumour sample access. Previous treatment using a MEK inhibitor or any other regimen containing docetaxel (previous treatment with paclitaxel is accepted)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>The frequency and type of KRAS mutation in a sample of the Brazilian population with advanced NSCLC</keyword>
	<keyword>KRAS mutation in population with advanced NSCLC</keyword>
</DOC>